Glaukos (GKOS) News Mentions Statistics 2024

1 75%

1W 0% 1M 0% 3M 0%

Est. daily news mentions.

Similar companies

Company		News Mentions
	Boston Scientific BSX	0 0%
	Edwards Lifesciences EW	0 0%
	Intuitive Surgical ISRG	0 0%
	Medtronic MDT	0 0%
	Stryker SYK	1 0%

Glaukos Co. (NYSE:GKOS) Receives Average Rating of “Moderate Buy” from Brokerages

December 24

The three-year returns have been stellar for Glaukos (NYSE:GKOS) shareholders despite underlying losses increasing

December 21

Glaukos: Still Bullish, But Embedded Expectations Are Now High

December 20

Glaukos (NYSE:GKOS) Sets New 12-Month High on Analyst Upgrade

December 19

Glaukos price target raised to $185 from $152 at Truist

December 18

Glaukos Co. (NYSE:GKOS) Short Interest Down 5.3% in November

December 17

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

December 16

3,100 Shares in Glaukos Co. (NYSE:GKOS) Bought by XTX Topco Ltd

December 16

Month over Month

Est. daily news mentions.

Nov 2024	0	45.3%
Oct 2024	1	26.6%
Sep 2024	0	123.9%
Aug 2024	0
Jul 2024	0	0%

How often is Glaukos mentioned in the news?

Glaukos was mentioned an estimated 1 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Glaukos performing compared to its industry peers?

Glaukos overperforms all of its industry peers when it comes to News Mentions, having more News Mentions than any of its peers.

Has there been an increase or decrease in news mentions of Glaukos in the last month?

There has been no significant change in the number of news mentions for Glaukos' compared to the last month.

Why is it important to track news mentions for Glaukos?

By monitoring mentions in the news for Glaukos, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Glaukos, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

Top Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact

Glaukos (GKOS) - News Mentions

Similar companies

Boston Scientific

Edwards Lifesciences

Intuitive Surgical

Medtronic

Stryker

Glaukos Co. (NYSE:GKOS) Receives Average Rating of “Moderate Buy” from Brokerages

Glaukos Co. (NYSE:GKOS) Shares Sold by Principal Financial Group Inc.

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman Sells 10,000 Shares

Joseph E. Gilliam Sells 3,328 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos president sells $498,715 in stock

Glaukos Submits New Drug Application to U.S. FDA for Epioxa

Glaukos director Gilbert H. Kliman sells shares worth $1.5 million

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™